Zoladex stays on PBS until May 2027 — what this means for you

Good news arrived this morning, but it comes with a timeline. According to newsGP, AstraZeneca has confirmed the Zoladex monthly 3.6 mg implant will remain on the Pharmaceutical Benefits Scheme until 1 May 2027 — a six-month extension on the 1 November 2026 delisting date that had been quietly announced earlier this year. Prescriptions written before 30 April 2027 can be dispensed until 1 May 2028.

The original delisting announcement generated swift and significant backlash. Patients using Zoladex for endometriosis, uterine fibroids, and hormone-receptor-positive breast cancer — and the GPs managing their care — made clear that a sudden removal from the PBS without a clear equivalent pathway represented a real disruption to treatment. AstraZeneca heard it.

What they have also confirmed: the company’s previously announced Zoladex continuity program will not proceed. That framing matters. The extension preserves access for now. It is not a commitment to the product beyond May 2027.

---

What this drug actually does, and who uses it

Goserelin is a GnRH agonist — it works by suppressing the body’s production of oestrogen and testosterone through a downregulation effect on the pituitary gland. In women, this creates a temporary, reversible state of medically-induced low oestrogen. That mechanism is useful in three main clinical scenarios.

Endometriosis. Endometrial tissue outside the uterus responds to oestrogen in the same way as tissue inside it — growing through the cycle and causing inflammation, adhesions, and pain. Suppressing oestrogen via goserelin can reduce lesion activity and significantly reduce pelvic pain, particularly where surgery is not preferred or as post-surgical maintenance. According to Healthdirect Australia, endometriosis affects roughly 1 in 9 Australian women of reproductive age — about 830,000 people.

Uterine fibroids. Pre-operatively, or as a holding measure, goserelin can reduce fibroid size and associated heavy menstrual bleeding.

Breast cancer adjuvant therapy. In premenopausal women with hormone-receptor-positive breast cancer, suppressing ovarian oestrogen production is a component of adjuvant treatment — often used alongside aromatase inhibitors or tamoxifen. The three-monthly 10.8 mg goserelin implant is now TGA-registered for this indication and is currently undergoing PBAC evaluation for PBS listing.

The monthly implant was dispensed 92,191 times in the 12 months to May 2026. Those are not small numbers. They describe a significant patient cohort — most of them women — relying on stable PBS access to manage a chronic condition.

---

The contested part

The tension here is not about whether goserelin works — the evidence base is well-established. The tension is structural.

AstraZeneca has stated that Zoladex is expensive to manufacture and that years of inflation have increased production costs. The PBS pricing framework, which locks in the price the government pays at the time of listing, has not kept pace. That is a legitimate commercial argument, and it is not isolated to this drug — it is a feature of how the PBS interacts with older off-patent medications across several categories.

The other side of that argument is patient need. For conditions like endometriosis, which took an average of 8.6 years to diagnose in Australia as recently as 2019 (per Jean Hailes), access to effective, PBS-subsidised treatment once a diagnosis is finally reached should not be a moving target.

AstraZeneca is reportedly considering a further application for long-term reimbursed access. The PBAC process will take time. Triptorelin (Diphereline) 3.75 mg is now PBS-listed as an alternative from 1 October 2026 — but GnRH agonists are not automatically interchangeable. Different PBS indications, different titration data, different patient experiences.

There is also a real question about what happens after May 2027 if the PBAC evaluation of the three-monthly formulation is not complete, or if no further application is lodged for the monthly implant.

---

What this means this week

If you are currently on Zoladex, nothing changes until at least May 2027. Your current supply chain is intact. Prescriptions written before 30 April 2027 can be filled until 1 May 2028 — which gives some buffer even beyond the delisting date.

Have the transition conversation now, not in March 2027. If you are on Zoladex for endometriosis or fibroids, ask your GP or specialist at your next review what the plan looks like if the listing is not renewed. Understanding whether triptorelin is appropriate for your specific indication is a useful data point — not because you need to switch now, but because a six-month warning period with an informed plan is better than a six-month panic.

If you have breast cancer and are on Zoladex as part of adjuvant therapy, speak with your oncologist. The three-monthly 10.8 mg formulation is being evaluated for PBS listing specifically for this indication and may offer a path forward — but that evaluation has its own timeline.

GPs: this is worth flagging proactively. Many patients will not have seen the AstraZeneca announcement or the newsGP story. A short note at review — “just so you know, Zoladex will stay on the PBS until May 2027 while alternatives are being assessed” — is the kind of information that reduces anxiety, preserves trust, and gives people time.

The extension is good news. The continuity program not proceeding is the footnote the extension shouldn’t let you miss.

Verdict: yes — if you or a patient you are seeing uses Zoladex, the timeline needs to be on your radar now.

---

Sources cited

1. PBS access to Zoladex extended — newsGP, 24 September 2026
2. Endometriosis — Healthdirect Australia
3. Endometriosis diagnosis time — Jean Hailes for Women’s Health
4. Pharmaceutical Benefits Scheme